Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

摘要：在新一代口服肥胖症药物 III 期数据不及预期后，制药巨头礼来（Eli Lilly）迅速出手，以 13 亿美元与波士顿 AI/机器学习初创公司 Superluminal Medicines 达成合作，聚焦 G ...

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

markdown 礼来（Eli Lilly）近日宣布与Superluminal Medicines达成合作，斥资高达13亿美元（约合93亿元人民币），共同开发针对心脏代谢疾病和肥胖的GPCR靶点小分子新药。这一合作标志着 AI+蛋白质动力学 ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. When a caller inquired about the company ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...